Banca de QUALIFICAÇÃO: ISABELA PESSOA BARBIERI BASTOS

Uma banca de QUALIFICAÇÃO de MESTRADO foi cadastrada pelo programa.
STUDENT : ISABELA PESSOA BARBIERI BASTOS
DATE: 05/02/2026
TIME: 08:00
LOCAL: Online
TITLE:

Use of 1% nanocyclosporine in the treatment of keratoconjunctivitis sicca in dogs.

KEY WORDS:

Dry keratoconjunctivitis, Nanociclosporine.

PAGES: 9
BIG AREA: Ciências Agrárias
AREA: Medicina Veterinária
SUMMARY:

One of the most frequent ophthalmic diseases in dogs is keratoconjunctivitis sicca. This condition
is characterized by aqueous deficiency of the tear film, leading to clinical signs of
ocular discomfort, accumulation of secretion, and inflammation of the cornea and conjunctiva, which can worsen
and lead to visual loss. Treatment of keratoconjunctivitis sicca is one of the great challenges in this
scenario, as it demands continuous topical therapy, which is often discontinued by owners due to cost, management, or even long-term adverse effects. Cyclosporine is
an immunomodulatory drug already well known in the treatment of keratoconjunctivitis sicca in dogs, with proven efficacy. The formulation of this drug in a nanocarrier system has not yet been studied in dry eye and may offer advantages such as ease of drug dispersion in water and its manipulation in aqueous bases (allowing the obtaining of stable formulas with a more pleasant sensory experience), prolonged release of cyclosporine, reduction of adverse reactions, potentiation of the effect, and reduction of treatment costs. This work aims to evaluate the efficacy of 1% nanocyclosporine-based eye drops in the treatment of keratoconjunctivitis sicca in dogs. For this evaluation, canine patients diagnosed with keratoconjunctivitis sicca will be used, using the Schirmer Tear Test showing a value below 15 mm/min, and the presence of typical clinical signs of the disease through evaluation with a slit-lamp biomicroscope (which include the presence of secretion, conjunctival hyperemia, neovascularization, and corneal pigmentation). These patients will be classified as having mild, moderate, and severe keratoconjunctivitis sicca according to the clinical signs involved and the Schirmer test value. The animals will then be divided into two experimental groups: the test group, which will undergo treatment with nanocyclosporine at a concentration of 1% manipulated in an aqueous-based vehicle, and the control group, which will receive a lubricating eye drop based on sodium carmellose. Both groups will be treated with an application frequency every 12 hours for a period of 60 days. Patients will be evaluated every 15 days by means of biomicroscopy examination with a slit lamp (to verify clinical signs) and the Schirmer tear test, these being the parameters used to determine the effectiveness of the medication. At the end of the study, it is expected to confirm the hypothesis that nanocyclosporine 1% eye drops are an effective medication in the treatment of dry eye in dogs and may be an alternative for manipulation in higher concentrations in aqueous vehicles, with fewer adverse effects and lower cost.

 

COMMITTEE MEMBERS:
Interno - 387015 - FERNANDO QUEIROZ DE ALMEIDA
Interno - 4563410 - JULIO ISRAEL FERNANDES
Interna - 6387102 - MARILENE DE FARIAS BRITO QUEIROZ